Unknown

Dataset Information

0

RCAN-11R peptide provides immunosuppression for fully mismatched islet allografts in mice.


ABSTRACT: Calcineurin inhibitors have been used for transplant therapy. However, the inhibition of calcineurin outside the immune system has a number of side effects. We previously developed a cell-permeable inhibitor of NFAT (nuclear factor of activated T cells) using the polyarginine peptide delivery system. This peptide (11R-VIVIT) selectively interferes with calcineurin-NFAT interaction without affecting the activity of calcineurin phosphatase and provides immunosuppression for fully mismatched islet allografts in mice. However, our recent study showed that 11R-VIVIT affected cell viability in vitro when it was used at higher concentration because of the VIVIT sequence. The aim of this study is to develop a safer NFAT inhibitor (RCAN-11R) that does not affect cell viability, and which is less toxic than calcineurin inhibitors. The minimal sequence of the protein family of regulators of calcineurin (RCAN) that is responsible for the inhibition of calcineurin-NFAT signaling was recently characterized. The peptide could selectively interfere with the calcineurin-NFAT interaction without affecting the activity of calcineurin phosphatase, similar to 11R-VIVIT. RCAN-11R did not affect cell viability when it was used at a higher concentration than the toxic concentration of 11R-VIVIT. RCAN-11R could therefore be useful as a therapeutic agent that is less toxic than current drugs or 11R-VIVIT.

SUBMITTER: Noguchi H 

PROVIDER: S-EPMC5465209 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

RCAN-11R peptide provides immunosuppression for fully mismatched islet allografts in mice.

Noguchi Hirofumi H   Sugimoto Koji K   Miyagi-Shiohira Chika C   Nakashima Yoshiki Y   Kobayashi Naoya N   Saitoh Issei I   Watanabe Masami M   Noguchi Yasufumi Y  

Scientific reports 20170608 1


Calcineurin inhibitors have been used for transplant therapy. However, the inhibition of calcineurin outside the immune system has a number of side effects. We previously developed a cell-permeable inhibitor of NFAT (nuclear factor of activated T cells) using the polyarginine peptide delivery system. This peptide (11R-VIVIT) selectively interferes with calcineurin-NFAT interaction without affecting the activity of calcineurin phosphatase and provides immunosuppression for fully mismatched islet  ...[more]

Similar Datasets

| S-EPMC9804298 | biostudies-literature
| S-EPMC2323197 | biostudies-literature
| S-EPMC6613183 | biostudies-literature
| S-EPMC2927949 | biostudies-literature
| S-EPMC5964538 | biostudies-literature
| S-EPMC9106299 | biostudies-literature
2024-06-13 | GSE269828 | GEO
| S-EPMC4649719 | biostudies-other
| S-EPMC7517581 | biostudies-literature
| S-EPMC10040375 | biostudies-literature